---
title: "Mangoceuticals 10-K: Revenue $0.456M, EPS loss $(2.17)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281349743.md"
description: "Mangoceuticals reported annual revenue of $0.456 million, down from $0.616 million the previous year, with a net loss of $(20.643) million, compared to $(8.707) million last year. The basic and diluted loss per share was $(2.17). The revenue decline was attributed to issues during a platform migration and relaunch, alongside increased operational costs. The company is focusing on telemedicine services and investing in technology and staffing to support future growth."
datetime: "2026-04-01T10:35:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281349743.md)
  - [en](https://longbridge.com/en/news/281349743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281349743.md)
---

# Mangoceuticals 10-K: Revenue $0.456M, EPS loss $(2.17)

Mangoceuticals reported annual revenue of $0.456 million and a basic and diluted loss per share of $(2.17) for the year, with revenue declines linked to a platform migration and relaunch. The company posted a net loss of $(20.643) million, driven by increased stock‑based compensation, amortization and impairment charges, and higher general and administrative and investor relations expenses. Operating loss widened substantially as Mangoceuticals invested in technology, staffing and public awareness during the transition.

**Financial Highlights**

-   **Revenues:** $0.456 million (down from $0.616 million in the prior year)
-   **Gross profit:** $0.250 million (down from $0.380 million in the prior year)
-   **Loss from operations:** $(18.032) million
-   **Net loss:** $(20.643) million (prior year: $(8.707) million)
-   **Basic and diluted loss per share:** $(2.17); weighted average shares outstanding: 10,071,609 (prior year: $(4.80) on 1,978,966)

**Business Highlights**

-   **Platform transition and relaunch:** Revenue decline was primarily driven by migration issues during a telemedicine platform relaunch.
-   **Product and channel focus:** Continued emphasis on telemedicine services with a focus on men’s health pharmaceutical products and customer service support.
-   **Marketing and investor outreach:** Advertising spend was reduced during the website relaunch while investor relations and public awareness activities increased.
-   **Operational investments:** Ongoing technology enhancements, platform migration efforts, patent/license acquisitions, and staffing increases to support future growth.

Original SEC Filing: MANGOCEUTICALS, INC. \[ MGRX \] - 10-K - Apr. 01, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [MGRX.US](https://longbridge.com/en/quote/MGRX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026](https://longbridge.com/en/news/287081023.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)